BARD1 Antikörper (N-Term)

Produktnummer ABIN950603

Der Kaninchen Polyklonal anti-BARD1 Antikörper wird verwendet zum Nachweis von BARD1 in Proben von Human. Er wurde validiert für WB und EIA.

Kurzübersicht für BARD1 Antikörper (N-Term) (ABIN950603)

Target: BARD1 (BRCA1 Associated RING Domain 1 (BARD1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser BARD1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Produktdetails anti-BARD1 Antikörper

Bindungsspezifität: AA 104-135, N-Term

Spezifität: This antibody reacts to BARD1.

Kreuzreaktivität (Details): Species reactivity (tested):Human.

Aufreinigung: Affinity chromatography on Protein A

Immunogen: KLH conjugated synthetic peptide between 104-135 amino acids from the N-terminal region of human BARD1.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) sodium azide as preservative

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu BARD1

Target: BARD1 (BRCA1 Associated RING Domain 1 (BARD1))

Andere Bezeichnung: BARD1

Hintergrund: BARD1 is a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer.Synonyms: BARD-1, BRCA1-associated RING domain protein 1

Gen-ID: 580

NCBI Accession: NP_000456

Pathways: DNA Reparatur